1817 – Xeomin (incobotulinumtoxinA) injection codes for lower limb spasticity following an acute event

Change to an existing Medicare Benefits Schedule item.

IncobotulinumtoxinA (Xeomin) is a purified formulation of botulinum neurotoxin that can be used to treat a range of neurological conditions. The service being requested in this application is the administration of the incobotulinumtoxinA injection to reduce muscle spasms, facilitating mobility and dexterity, improving patient ease of care as well as hygiene/selfcare, facilitating brace use, improving posture, minimizing contractures and deformity as well as reducing pain. 

Type: Therapeutic

Spasticity of the lower limb is a disabling complication as a result of a stroke that leads to pain, abnormal gait, functional disability, and reduced quality of life. It also may increase caregiver burden, health resource utilisation, and long-term healthcare costs due to falls, contractures, and institutionalisation. 

Up to 40% of stroke survivors following stroke experience lower limb spasticity manifested within the first month following a stroke. Spasticity of the lower limb can affect ankle plantar flexors and cause equinovarus deformities resulting in impairment of movement and quality of life. 

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Bypassing PASC
• Pre-MSAC consultation deadline: 20 February 2026 11:59pm AEDT

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: Bypassing PASC
• ESC meeting: Bypassing ESC
• MSAC meeting: 1 to 2 April 2026

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.